Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol – Will AI Replace Clinicians?
-
Sep 14, 2026, 07:19Ruhi Mehra: The Evolving Science of Stem Cell Enumeration
-
Sep 14, 2026, 07:05Don’t Overlook Superficial Clots – World Thrombosis Day
-
Sep 14, 2026, 06:55Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group
-
Sep 14, 2026, 06:51Alexander Hof: Species-Specific Roles of MPO Deficiency
-
Sep 14, 2026, 06:36Patrick Badertscher: PVI With vs Without Posterior Wall Isolation in Persistent AF
-
Sep 14, 2026, 06:31Mona Ranade: Can Mechanical Thrombectomy Play a Role in Septic Thrombophlebitis?